Wechselwirkungen · Cubicin
Cubicin 350 mg powder for solution for injection or infusion Cubicin 500 mg powder for solution for injection or infusion · Abschnitt 4.5 · PDF-Seite 8
HOS-114907 · Präparat HOS-094185
During post–marketing surveillance, cases of interference between daptomycin and particular reagents used in some assays of prothrombin time/international normalised ratio (PT/INR) have been reported. This interference led to a false prolongation of PT and elevation of INR. If unexplained abnormalities of PT/INR are observed in patients taking daptomycin, consideration should be given to a possible in vitro interaction with the laboratory test. The possibility of erroneous results may be minimised by drawing samples for PT or INR testing near the time of trough plasma concentrations of daptomycin (see section 4.4).
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): prothrombin (HOS-085093)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-07T17:00:00Z · SHA-256 78f13e63eae9a874aa191edfcc08896bf444b0cbc172e2987afdd1ea4ebf1338 · Passage f3ad967d6aa0eb47917ad3ba25d39fb59bde16997c5098e44505452e8230130b · Zeichen 2593–3215 im Abschnitt